<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05012423</url>
  </required_header>
  <id_info>
    <org_study_id>EC0001</org_study_id>
    <nct_id>NCT05012423</nct_id>
  </id_info>
  <brief_title>FTIH Study of ECC0509 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Ecc0509 In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eccanga Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eccogene (Shanghai) Co. Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple&#xD;
      Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability,&#xD;
      Pharmacokinetics, and Pharmacodynamics of ECC0509 in Healthy Volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in up to seven cohorts of Single Ascending Dose (SAD) &amp; 3&#xD;
      cohorts of Multiple Ascending Dose (MAD). SAD will consist of a staggered dosing approach&#xD;
      with a dose range from 1mg to 80mg. Staggered dosing approach will not be deployed for MAD&#xD;
      cohorts with a dose range of 8mg to 40mg. In the MAD cohort, the effect of food will also be&#xD;
      assessed by comparing the PK profile of Day 10 fed conditions against Day 14 fasted&#xD;
      conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">February 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events and serious adverse events</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>An adverse event is any untoward medical occurrence in a clinical study subject, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Serious adverse event is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal values for blood pressure</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Systolic and diastolic blood pressure of subjects will be measured in a semi-supine position after at least 5 minutes of rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal values for pulse rate</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Pulse rate of subjects will be measured in a semi-supine or supine position after at least 5 minutes of rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal values for respiratory rate</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Respiratory rate of subjects will be measured in a semi-supine position after at least 5 minutes of rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal values for tympanic temperature</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Tympanic temperature of subjects will be measured in a semi-supine position after at least 5 minutes of rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal values for electrocardiogram parameters</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>12-lead electrocardiogram will be obtained using an electrocardiogram machine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal findings for clinical chemistry parameters</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Blood samples will be collected from subjects for analysis of clinical chemistry parameters including urea, potassium, AST, total bilirubin, direct bilirubin, creatinine sodium bicarbonate, chloride, ALT, albumin, glucose, calcium, phosphate, alkaline phosphatase, cholesterol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal findings for hematology parameters</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Blood samples will be collected from subjects for analysis of hematology parameters including platelet count, mean platelet volume, mean cell volume, mean cell hemoglobin, mean corpuscular hemoglobin concentration, white blood cells count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, red blood cells count, hemoglobin and hematocrit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal findings for coagulation parameters</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Blood samples will be collected from subjects for analysis of coagulation parameters including Activated Thromboplastin Time, Prothrombin Time and International Normalized Ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal findings for urinalysis parameters</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Urine samples will be collected from subjects for analysis of specific gravity, potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine by dipstick test. Microscopic examination will be performed if blood or protein is abnormal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 1</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 2</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 3</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Time of peak plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 4</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Half life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 5</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Apparent total clearance after oral administration (Cl/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment 6</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Apparent volume of distribution during terminal phase after oral administration (Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic assessment</measure>
    <time_frame>SAD: Up to Day 8. MAD: Up to Day 21.</time_frame>
    <description>Plasma Semicarbazide-Sensitive Amine Oxidase (SSAO) Activity</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>SAD Cohorts 1 to 7: Participants Receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in each SAD cohort will be randomized to receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohorts 1 to 7: Participants receiving ECC0509</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in each SAD cohort will be randomized to receive 1 of 7 escalating doses (1 mg, 4 mg, 10 mg, 20 mg, 40 mg, 60 mg, or 80 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohorts 1 to 3: Participants receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to receive a once-daily dose of placebo for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohorts 1 to 3: Participants receiving ECC0509</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive a once-daily dose of 1 of 3 escalating doses (8 mg, 20 mg, or 40 mg) for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo&#xD;
Placebo will be administered as oral capsules.</description>
    <arm_group_label>SAD Cohorts 1 to 7: Participants Receiving Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ECC0509</intervention_name>
    <description>ECC0509 1 mg and 10 mg capsules&#xD;
ECC0509 will be administered as oral capsules.</description>
    <arm_group_label>SAD Cohorts 1 to 7: Participants receiving ECC0509</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo&#xD;
Placebo will be given orally during each dosing day.</description>
    <arm_group_label>MAD Cohorts 1 to 3: Participants receiving Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ECC0509</intervention_name>
    <description>ECC0509 1 mg and 10 mg capsules&#xD;
Placebo will be given orally during each dosing day.</description>
    <arm_group_label>MAD Cohorts 1 to 3: Participants receiving ECC0509</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or non-childbearing potential female&#xD;
&#xD;
          2. Age ≥18 and ≤65 years old&#xD;
&#xD;
          3. BMI ≥18.0 and ≤32.0 kg/m2&#xD;
&#xD;
          4. Male participants agree to use contraception&#xD;
&#xD;
          5. No clinically significant abnormal findings in physical examination, 12-lead&#xD;
             electrocardiogram (ECG), laboratory tests, or medical history&#xD;
&#xD;
          6. Able to understand and sign informed consent&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Significant allergic reactions to any drug.&#xD;
&#xD;
          2. History of significant drug abuse or alcohol abuse within 1 year prior to screening&#xD;
&#xD;
          3. Concomitant participation in any investigational study of any nature&#xD;
&#xD;
          4. Use of any concomitant medication except for the occasional use of acetaminophen (up&#xD;
             to 2 g daily)&#xD;
&#xD;
          5. Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more&#xD;
             of whole blood within 8 weeks prior to dosing.&#xD;
&#xD;
          6. Any clinically significant abnormal findings in the participant's physical&#xD;
             examination, laboratory tests, pregnancy test, urine drug screen, alcohol breath test,&#xD;
             or medical history which, in the opinion of the Investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Participant Engagement Manager</last_name>
    <phone>1800150433</phone>
    <email>cmax@cmax.com.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>CMAX Clinical Research</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Participant Engagement Manager</last_name>
      <phone>1800150433</phone>
      <email>cmax@cmax.com.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

